Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the ADDF awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.
The ADDF announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109.
Alzheimer’s Drug Discovery Foundation an Official Charity Partner of 2015 TCS New York City Marathon
The ADDF is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon.
The ADDF and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.
The ADDF announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).
The ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer’s disease by targeting inflammation. This grant follows two previous awards by ADDF to Axxam in 2011 and 2013. The award will continue to fund a drug discovery project to identify compounds that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain.
Today, the ADDF and the Alzheimer’s Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership.
On Monday, former model and restaurateur B. Smith was honored by the ADDF at its Fifth Annual Fall Symposium & Luncheon. Smith, who publicly revealed her early-onset Alzheimer’s diagnosis in June, was presented with The Charles Evans Award at Monday’s Luncheon for using her powerful platform to promote public awareness and raise critical funds to combat Alzheimer’s disease.
The ADDF and OnDeckBiotech announced today the launch of ADDF ACCESS, a new and improved open access platform to connect scientists with a virtual network of contract research organizations (CROs), drug development experts and educational resources.
A new peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of FDA-approved drugs for the treatment of neurodegenerative diseases.